Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.5% – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares were down 5.5% during trading on Tuesday . The company traded as low as $23.45 and last traded at $23.01. Approximately 14,342 shares changed hands during trading, a decline of 94% from the average daily volume of 224,916 shares. The stock had previously closed at $24.34.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DNTH shares. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday. Guggenheim reiterated a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Trading Down 2.9 %

The company has a market cap of $629.38 million, a price-to-earnings ratio of -8.51 and a beta of 1.82. The firm has a 50-day moving average price of $22.65 and a 200 day moving average price of $24.94.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Management LLC raised its stake in Dianthus Therapeutics by 3.1% during the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after acquiring an additional 433 shares in the last quarter. Invesco Ltd. raised its stake in shares of Dianthus Therapeutics by 7.4% in the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock worth $251,000 after buying an additional 790 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Dianthus Therapeutics by 9.2% in the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after acquiring an additional 814 shares during the last quarter. Barclays PLC grew its holdings in shares of Dianthus Therapeutics by 2.6% in the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock worth $933,000 after acquiring an additional 1,082 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Dianthus Therapeutics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock worth $3,641,000 after acquiring an additional 1,092 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.